The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Neparvis sacubitril;valsartan | Novartis Europharm Limited | Heart Failure | 🇪🇺 EU 2016-05-26 | Order → |
| Palonosetron Accord palonosetron Generic | Accord Healthcare S.L.U. | Vomiting; Nausea; Cancer | 🇪🇺 EU 2016-05-26 | Order → |
| Strimvelis autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence OrphanATMPAdditional monitoring | Fondazione Telethon ETS | Severe Combined Immunodeficiency | 🇪🇺 EU 2016-05-26 | Order → |
| Galafold migalastat | Amicus Therapeutics Europe Limited | Fabry Disease | 🇪🇺 EU 2016-05-25 | Order → |
| Darzalex daratumumab Accelerated assessment | Multiple Myeloma | 🇪🇺 EU 2016-05-20 | Order → | |
| Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) pandemic influenza vaccine (H5N1) (live attenuated, nasal) ConditionalAdditional monitoring | AstraZeneca AB | Influenza, Human | 🇪🇺 EU 2016-05-20 | Order → |
| Alprolix eftrenonacog alfa Orphan | Swedish Orphan Biovitrum AB (publ) | Hemophilia B | 🇪🇺 EU 2016-05-12 | Order → |
| Uptravi selexipag | Janssen Cilag International NV | Hypertension, Pulmonary | 🇪🇺 EU 2016-05-12 | Order → |
| Empliciti elotuzumab Accelerated assessment | Bristol-Myers Squibb Pharma EEIG | Multiple Myeloma | 🇪🇺 EU 2016-05-11 | Order → |
| Idelvion albutrepenonacog alfa Orphan | CSL Behring GmbH | Hemophilia B | 🇪🇺 EU 2016-05-11 | Order → |
| Lonsurf trifluridine;tipiracil | Les Laboratoires Servier | Colorectal Neoplasms | 🇪🇺 EU 2016-04-25 | Order → |
| Taltz ixekizumab | Eli Lilly and Company (Ireland) Limited | Psoriasis; Arthritis, Psoriatic; Axial Spondyloarthritis; Arthritis, Juvenile | 🇪🇺 EU 2016-04-25 | Order → |
| Descovy emtricitabine;tenofovir alafenamide | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2016-04-21 | Order → |
| Palonosetron Hospira palonosetron Generic | Pfizer Europe MA EEIG | Nausea; Vomiting; Cancer | 🇪🇺 EU 2016-04-08 | Order → |
| Rasagiline Viatris (previously Rasagiline Mylan) rasagiline Generic | Viatris Limited | Parkinson Disease | 🇪🇺 EU 2016-04-04 | Order → |
| Wakix pitolisant OrphanAdditional monitoring | Bioprojet Pharma | Narcolepsy | 🇪🇺 EU 2016-03-31 | Order → |
| Zonisamide Viatris (previously Zonisamide Mylan) zonisamide Generic | Viatris Limited | Epilepsy | 🇪🇺 EU 2016-03-31 | Order → |
| Amlodipine / Valsartan Mylan amlodipine;valsartan Generic | Mylan Pharmaceuticals Limited | Hypertension | 🇪🇺 EU 2016-03-22 | Order → |
| Coagadex human coagulation factor X OrphanAccelerated assessment | Kedrion S.p.A. | Factor X Deficiency | 🇪🇺 EU 2016-03-16 | Order → |
| Neofordex dexamethasone | THERAVIA | Multiple Myeloma | 🇪🇺 EU 2016-03-16 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.